New York 2025-2026 Regular Session

New York Senate Bill S05284

Introduced
2/20/25  
Refer
2/20/25  

Caption

Relates to cannabinoid hemp retail sales and retailers; makes technical changes to the definition of THC; provides specific requirements for labeling of cannabinoid hemp products.

Summary

Bill S05284 seeks to amend the cannabis law in New York, specifically addressing the retail sales of cannabinoid hemp and the definitions related to THC. The bill clarifies the definitions of THC and total THC, ensuring that they encompass Delta-8 and Delta-10 tetrahydrocannabinols. Additionally, it establishes regulations for the sale of cannabinoid hemp products, particularly those intended for smoking, which must be sold exclusively in licensed adult-use cannabis dispensaries to individuals aged 21 and older. Furthermore, the bill mandates that processors create a code for product labels and adhere to specific labeling requirements, including nutrition information and warnings regarding the product's regulatory status.

Impact

The passage of S05284 would have a significant impact on the regulation of cannabinoid hemp products in New York. It would enhance consumer safety by enforcing strict labeling requirements that inform consumers about serving sizes, potency, and the non-medical nature of these products. Additionally, by restricting the sale of certain products to licensed dispensaries, the bill aims to regulate the market more effectively and prevent underage access to these products. This could lead to a more organized and safer retail environment for cannabinoid hemp products in the state.

Sentiment

The sentiment surrounding Bill S05284 appears to be generally supportive, as it addresses important regulatory gaps in the current cannabis law. Stakeholders in the cannabis industry, including retailers and processors, have expressed a need for clearer definitions and labeling standards to ensure compliance and consumer safety. However, there may be some concerns regarding the implications of restricting sales to licensed dispensaries and how this could affect smaller retailers or those looking to enter the market.

Contention

Notable points of contention may arise from the restrictions placed on the sale of cannabinoid hemp products, particularly the requirement that they only be sold in licensed adult-use dispensaries. Some stakeholders may argue that this could limit access for consumers who prefer to purchase these products from alternative sources. Additionally, the specific labeling requirements could be seen as burdensome by smaller processors who may struggle to meet the new regulations without incurring additional costs.

Companion Bills

NY A04367

Same As Relates to cannabinoid hemp retail sales and retailers; makes technical changes to the definition of THC; provides specific requirements for labeling of cannabinoid hemp products.

Previously Filed As

NY A04367

Relates to cannabinoid hemp retail sales and retailers; makes technical changes to the definition of THC; provides specific requirements for labeling of cannabinoid hemp products.

NY SB00970

An Act Concerning Cannabinoids, Hemp And Hemp Products.

NY HB346

Hemp Products & Synthetic Cannabinoids

NY S0137

Hemp-Derived Cannabinoids

NY AB8

Cannabis: cannabinoids: industrial hemp.

NY SB3206

Relating To Cannabinoids.

NY SB292

Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.

NY SB682

Regulating hemp-derived cannabinoid products.

NY AB747

Regulating hemp-derived cannabinoid products.

NY HB265

Georgia Hemp Farming Act; provide limits on the total concentration of THC and other intoxicating cannabinoids in consumable hemp products

Similar Bills

No similar bills found.